Funding
Innova Biosciences Ltd of Cambridge, a specialist in bioconjugation, has been awarded €455,000 of a €3,000,000 European grant, as part of the PROACTIVE consortium. Innova joins Olink, Copenhagen University, Fujirebio Diagnostics AB, Uppsala University, and Integromics SL in the project, which aims to develop a high throughput blood screening platform for the discovery of biomarkers of early stage cancer.
Innova Biosciences Lightning-Link bioconjugation products, which provide a simple method for joining biomolecules, will be central to this project. Nick Gee, CEO, said, “We are delighted to be granted such a prestigious award which recognises Innova’s proprietary knowledge and expertise. Participating in the development of a new immunodiagnostic platform that will facilitate early stage cancer detection is an exciting application of our technology.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.